# NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

> **NCT02429804** · PHASE1 · TERMINATED · sponsor: **Stanford University** · enrollment: 4 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Prostate Carcinoma

## Interventions

- **PROCEDURE:** Contrast-enhanced Magnetic Resonance Imaging
- **DRUG:** Fludeoxyglucose F-18
- **DRUG:** Fluorine F 18 Sodium Fluoride
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT02429804
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2017-05-15
- **Final completion:** 2017-05-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Accrual factor
- **Last updated:** 2017-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429804, "NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02429804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*